Teachers Retirement System of The State of Kentucky Sells 800 Shares of Repligen Co. (NASDAQ:RGEN)

Teachers Retirement System of The State of Kentucky reduced its position in shares of Repligen Co. (NASDAQ:RGEN) by 4.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 16,858 shares of the biotechnology company’s stock after selling 800 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Repligen were worth $3,031,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Neo Ivy Capital Management bought a new stake in shares of Repligen during the 4th quarter valued at about $164,000. V Square Quantitative Management LLC grew its stake in shares of Repligen by 76.8% during the 4th quarter. V Square Quantitative Management LLC now owns 564 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 245 shares during the period. Harbert Fund Advisors Inc. bought a new stake in shares of Repligen during the 4th quarter valued at about $764,000. Brown Capital Management LLC grew its stake in shares of Repligen by 5.8% during the 4th quarter. Brown Capital Management LLC now owns 1,525,064 shares of the biotechnology company’s stock valued at $274,207,000 after acquiring an additional 83,416 shares during the period. Finally, Iron Triangle Partners LP bought a new position in shares of Repligen during the 4th quarter valued at approximately $14,840,000. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on RGEN. Guggenheim began coverage on Repligen in a research note on Tuesday. They set a “neutral” rating for the company. JPMorgan Chase & Co. cut their price objective on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Finally, Stifel Nicolaus boosted their price objective on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Repligen has an average rating of “Moderate Buy” and a consensus price target of $197.75.

Insider Transactions at Repligen

In other news, Director Martin D. Madaus acquired 1,615 shares of the firm’s stock in a transaction dated Friday, June 14th. The shares were acquired at an average cost of $124.94 per share, with a total value of $201,778.10. Following the acquisition, the director now directly owns 4,613 shares of the company’s stock, valued at $576,348.22. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Martin D. Madaus acquired 1,615 shares of the firm’s stock in a transaction dated Friday, June 14th. The shares were acquired at an average cost of $124.94 per share, with a total value of $201,778.10. Following the acquisition, the director now directly owns 4,613 shares of the company’s stock, valued at $576,348.22. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Anthony Hunt purchased 2,000 shares of the stock in a transaction that occurred on Friday, June 14th. The stock was bought at an average price of $124.08 per share, with a total value of $248,160.00. Following the completion of the transaction, the chief executive officer now owns 165,177 shares of the company’s stock, valued at $20,495,162.16. The disclosure for this purchase can be found here. Insiders own 1.20% of the company’s stock.

Repligen Trading Down 1.1 %

RGEN stock opened at $123.00 on Thursday. Repligen Co. has a 1-year low of $110.45 and a 1-year high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24. The company has a market capitalization of $6.87 billion, a price-to-earnings ratio of 492.02, a PEG ratio of 4.15 and a beta of 1.04. The business has a 50 day simple moving average of $157.34 and a two-hundred day simple moving average of $175.65.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.01). The firm had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. The firm’s revenue was down 17.1% on a year-over-year basis. During the same period last year, the company earned $0.64 earnings per share. Research analysts anticipate that Repligen Co. will post 1.46 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.